Luthra and Luthra Law Offices India represented Sapala Organics Private Limited and its existing shareholders in finalizing agreements with Suven Pharmaceuticals Limited for the acquisition of 100% equity shares (on a fully diluted basis)
Suven Pharmaceuticals Limited (“Suven”), one of India’s largest integrated CDMO players, has entered into a definitive agreement for a strategic controlling investment in Sapala Organics Private Limited (“Sapala”), subject to regulatory approvals and conditions.
The transaction was led by Luthra and Luthra Law Offices India’s Partner Nishant Singh, the transaction team included Managing Associate Saksham Madan and Associates Varshini Ramesh, Charith Reddy, and Maitri Meghani.
SAPALA is a leading CRO/CMO that specializes in custom synthesis of various organic compounds. The Company helps with all areas of process development, drug discovery, medicinal chemistry, analytical services as well as manufacturing up to kg scale.
Suven Pharmaceuticals Limited, is a contract drug development and manufacturing (CDMO) services partner, built on more than 35 years of research, innovation, quality, and innovative technology capability.
Share your news, articles, deals, columns, or press releases with us! Click the link to submit and join our platform today.
